MOPC315.BM Multiple Myeloma Model

MOPC315.BM cells [20 (link)] was kindly provided by Prof. Bjarne Bogen (University of Oslo, Norway). They were cultured at 37 °C in 5% CO₂ in RPMI 1640 (Sigma-Aldrich, Rehovot, Israel) supplemented with 10% FBS, 1% MEM NEAA 100x (Gibco), 0.005% 1 M I-thioglycerol, 0.03% Gensumycin 40 mg/ml (Sigma-Aldrich) and 2 mM L-glutamine (Biological Industries, Beit Haemek, Israel). I.v. injection of MOPC315.BM cells results in tumor development in the bone marrow (BM) and spleen and is associated with osteolytic lesions, validating the model as resembling human MM disease [21 (link)]. In advanced disease stages (within 3–4 weeks), the mice develop paraplegia through spinal cord compression. They were sacrificed when presenting signs of paraplegia, deterioration of general condition or apathy.